PMID- 25477072
OWN - NLM
STAT- MEDLINE
DCOM- 20150821
LR  - 20211203
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1849
IP  - 7
DP  - 2015 Jul
TI  - Translational control by oncogenic signaling pathways.
PG  - 753-65
LID - S1874-9399(14)00290-9 [pii]
LID - 10.1016/j.bbagrm.2014.11.006 [doi]
AB  - Messenger RNA (mRNA) translation is highly regulated in cells and plays an 
      integral role in the overall process of gene expression. The initiation phase of 
      translation is considered to be the most rate-limiting and is often targeted by 
      oncogenic signaling pathways to promote global protein synthesis and the 
      selective translation of tumor-promoting mRNAs. Translational control is a 
      crucial component of cancer development as it allows cancer cells to adapt to the 
      altered metabolism that is generally associated with the tumor state. The 
      phosphoinositide 3-kinase (PI3K)/Akt and Ras/mitogen-activated protein kinase 
      (MAPK) pathways are strongly implicated in cancer etiology, and they exert their 
      biological effects by modulating both global and specific mRNA translation. In 
      addition to having respective translational targets, these pathways also impinge 
      on the mechanistic/mammalian target of rapamycin (mTOR), which acts as a critical 
      signaling node linking nutrient sensing to the coordinated regulation of cellular 
      metabolism. mTOR is best known as a central regulator of protein synthesis and 
      has been implicated in an increasing number of pathological conditions, including 
      cancer. In this article, we describe the current knowledge on the roles and 
      regulation of mRNA translation by various oncogenic signaling pathways, as well 
      as the relevance of these molecular mechanisms to human malignancies. This 
      article is part of a Special Issue entitled: Translation and cancer.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Gao, Beichen
AU  - Gao B
AD  - Institute for Research in Immunology and Cancer (IRIC), Universite de Montreal, 
      Montreal, Quebec, Canada.
FAU - Roux, Philippe P
AU  - Roux PP
AD  - Institute for Research in Immunology and Cancer (IRIC), Universite de Montreal, 
      Montreal, Quebec, Canada; Department of Pathology and Cell Biology, Faculty of 
      Medicine, Universite de Montreal, Montreal, Quebec, Canada. Electronic address: 
      philippe.roux@umontreal.ca.
LA  - eng
GR  - mop123408/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141202
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Animals
MH  - Extracellular Signal-Regulated MAP Kinases/genetics/metabolism
MH  - Humans
MH  - *MAP Kinase Signaling System
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - *Protein Biosynthesis
MH  - Proto-Oncogene Proteins c-akt/genetics/metabolism
MH  - RNA, Messenger/genetics/*metabolism
MH  - RNA, Neoplasm/genetics/*metabolism
MH  - TOR Serine-Threonine Kinases/genetics/metabolism
MH  - ras Proteins/genetics/metabolism
OTO - NOTNLM
OT  - Cancer
OT  - MAPK
OT  - Protein synthesis
OT  - mRNA translation
OT  - mTOR
OT  - mTORC1
EDAT- 2014/12/06 06:00
MHDA- 2015/08/22 06:00
CRDT- 2014/12/06 06:00
PHST- 2014/09/07 00:00 [received]
PHST- 2014/11/17 00:00 [revised]
PHST- 2014/11/19 00:00 [accepted]
PHST- 2014/12/06 06:00 [entrez]
PHST- 2014/12/06 06:00 [pubmed]
PHST- 2015/08/22 06:00 [medline]
AID - S1874-9399(14)00290-9 [pii]
AID - 10.1016/j.bbagrm.2014.11.006 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2015 Jul;1849(7):753-65. doi: 10.1016/j.bbagrm.2014.11.006. 
      Epub 2014 Dec 2.